TOVXのROE（自己資本利益率）は？

Theriva Biologics Inc.のROEは-139.35%です。

TOVXの配当利回りは？

Theriva Biologics Inc.の配当利回りは0.00%です。

TOVXの品質スコア（Quality Score）は？

当社のAIはTOVXの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

TOVXは今が買い時ですか？

当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

TOVXはどのセクターに属しますか？

Theriva Biologics Inc.はHealthcare >> Biotechnologyセクターに分類されます（NYSE MKT市場）

TOVX (NYSE MKT) 株価分析 | Theriva Biologics Inc.

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

TOVX AI Analysis Summary

Our AI summary for TOVX: Theriva Biologics Inc. (NYSE MKT), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -139.35%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

TOVX

Theriva Biologics Inc.

US:NYSE MKT STOCK Healthcare >> Biotechnology News 48

USD 0.23

-0.00 (-1.44%) Day Change

Watchlist Portfolio Compare Chart

0.14

D/E

-139.4%

ROE

-56.1%

ROA

0.00%

Div Yield

THERIVA BIOLOGICS INC.
TYPE: STOCK
MARKET: NYSE MKT

Compare Watchlist Myport

USD 0.23 Price -0.00 (-1.44%) Day Change	NEWS SCORE: 48

TOVX, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Deepscope 分析

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	48
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.23
PBV / Sector	0.68 / 44,105.10 GREAT
Earning Per Share	-0.46

PE / Sector	N/A / 19.37
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	0.12 M GREAT
Average 1W Daily Value	0.11 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-7,153.00 / 97.23
NPM Average (%) / Sector	-7,153.00 / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-56.10 / 185,260.64
ROA Average (%) / Sector	-51.06 / 36,684.64
ROA Change Average (%) / Sector	28.91 / 422,221.42 GREAT
ROE (%) / Sector	-139.35 / 243,761.81
ROE Average (%) / Sector	-104.07 / 48,758.38
ROE Change Average (%) / Sector	56.52 / 424,967.86 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

登録情報

Analyze Date	2026-08-06 08:00:48
Symbol	TOVX
Name	THERIVA BIOLOGICS INC.
Sector	Healthcare >> Biotechnology
Market	NYSE MKT
Listed Shares	45.89 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	10.48 / 9,702.21

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 9605 Medical Center Drive, Rockville, MD, United States, 20850

Phone: 301 417 4364

Website: https://therivabio.com

Sector: Healthcare >> Biotechnology

Description: Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.